<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308137</url>
  </required_header>
  <id_info>
    <org_study_id>Domperidone_MS01</org_study_id>
    <nct_id>NCT02308137</nct_id>
  </id_info>
  <brief_title>Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)</brief_title>
  <official_title>Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Innovates Health Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to determine if Domperidone in a dose of 40 mg daily
      can prevent worsening of walking ability in people secondary progressive MS. The number of
      participants in this study will be 62. A maximum of 75 people with secondary progressive MS
      will be included. Each patient will be followed for 12 months from inclusion. Domperidone is
      a medication which has been shown to increase levels of the hormone prolactin. The best
      understood function of prolactin is the stimulation of milk production in women after
      delivery. However, the increase in prolactin levels seen in patients treated with standard
      doses of Domperidone (in doses of up to 80mg per day) usually does not lead to clinical
      symptoms. Prolactin has been shown to improve myelin repair in mice. Domperidone therefore
      may also improve myelin repair in people with MS. Domperidone is currently approved in Canada
      to treat slow moving bowels and nausea, for instance in patients with Parkinson's Disease or
      Diabetes Mellitus, where too slowly moving bowels can cause constipation. Domperidone is
      available as a tablet that is usually taken four times per day. Doses up to 80mg per day may
      be used but we estimate that a dose of only 40mg daily will be needed to stimulate myelin
      repair. Domperidone is usually well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective

      To demonstrate non-futility of domperidone for reducing progression of disability, as
      measured with the timed 25 foot walk (T25FW), in secondary progressive Multiple Sclerosis
      (SPMS).

      Secondary objectives

        -  To assess the safety of domperidone in the study population for the duration of the
           study.

        -  To assess the effect of domperidone on hand dexterity as measured with the 9HPT

        -  To assess the effect of domperidone on cognition, as measured with the SDMT

        -  To assess the effect of domperidone on health related quality of life, as measured with
           the MSQOL-54

        -  To assess the effect of domperidone on fatigue, as measured with the MFIS

        -  To establish the Simon-2-stage model as a study model in MS research. The application of
           this methodology to studies in progressive MS will have important consequences for the
           design and conduct of clinical and translational research in progressive MS, in
           particular for phase II trials in progressive MS
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timed 25-Foot Walk (T25W)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>quantitative ambulation performance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>9-Hole Peg Test</measure>
    <time_frame>administered at baseline, one month, 6 months, and 12 months</time_frame>
    <description>brief, standardized, quantitative test of upper extremity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test</measure>
    <time_frame>administered at baseline, one month, 6 months, and 12 months</time_frame>
    <description>measures cognitive processing speed and working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Systems and Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>administered at baseline, one month, 6 months, and 12 months</time_frame>
    <description>EDSS is the standard measure of neurologic impairment that is used to describe disability in MS. The neurological assessment comprises seven functional systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>administered at baseline, one month, 6 months, and 12 months</time_frame>
    <description>structured, self-report questionnaire with 21 itmes concerning how fatigue impacts patient's life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Quality of Life Scale 54 item version</measure>
    <time_frame>administered at baseline, one month, 6 months, and 12 months</time_frame>
    <description>54-item multidimensional health-related quality of life measure that combines both generic and MS-specific items</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>Domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment: Oral domperidone four times daily Target dose: 40mg per day Duration: 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>Simon-2-stage design for domperidone futility</description>
    <arm_group_label>Domperidone</arm_group_label>
    <other_name>domperidone maleate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent obtained

          -  with Multiple Sclerosis, and with secondary progressive disease course

          -  screening Expanded Disability Status Scale (EDSS) score between 4.0 and 6.5 inclusive

          -  screening timed 25 foot walk (average of two trials) lof 9 seconds or more

        Exclusion Criteria:

          -  Long QT interval, defined as corrected QT interval of more than 470 msec in men and
             more than 450 msec in women on baseline ECG

          -  Patients with known long-QT syndrome

          -  Patients with known ventricular arrhythmia

          -  Patients with a known electrolyte disturbance

          -  Patients undergoing treatment with drugs that increase the QTc interval

          -  Patients undergoing treatment with drugs that inhibit CYP3A4, in particular:
             Ketoconazole, Fluconazole, Erythromycin, Clarithromycin, Ritonavir

          -  Patients with a history of breast cancer or carcinoma in situ

          -  Patients with known renal insufficiency

          -  Patients with known allergy or other intolerability to domperidone

          -  Patients currently using Fampridine or 4-aminopyridine

          -  Patients planning to start Fampridine or 4-aminopyridine during the study period

          -  Patients planning to start Baclofen or Tizanidine during the duration of the study

          -  Patients planning to increase or decrease their dose of Baclofen or Tizanidine during
             the study period

          -  Patients planning to receive treatment with Botulinum toxin in the leg muscles during
             the duration of the study

          -  Patients with a significiant hepatic impairment

          -  Patients with a prolactinoma

          -  Patients in whom gastrointestinal stimulation could be dangerous

          -  Patients using MAO inhibitors

          -  Patients with a history of breast cancer

          -  Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus W Koch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus W Koch, MD, PhD</last_name>
    <phone>403-944-2579</phone>
    <email>mwkoch@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luanne M Metz, MD</last_name>
    <phone>403-944-4241</phone>
    <email>lmetz@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Calgary MS Clinic at Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharanjit Kaur, MPH</last_name>
      <phone>403-944-2579</phone>
      <email>sharanjit.kaur2@albertahealthservices.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000 Sep 28;343(13):938-52. Review.</citation>
    <PMID>11006371</PMID>
  </reference>
  <reference>
    <citation>Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012 Apr;122(4):1180-8. doi: 10.1172/JCI58649. Epub 2012 Apr 2. Review.</citation>
    <PMID>22466660</PMID>
  </reference>
  <reference>
    <citation>Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989 Dec;112 ( Pt 6):1419-28.</citation>
    <PMID>2597989</PMID>
  </reference>
  <reference>
    <citation>Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012 Nov 5;8(11):647-56. doi: 10.1038/nrneurol.2012.168. Epub 2012 Sep 25. Review.</citation>
    <PMID>23007702</PMID>
  </reference>
  <reference>
    <citation>Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006 Apr;5(4):343-54. Review.</citation>
    <PMID>16545751</PMID>
  </reference>
  <reference>
    <citation>Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Br√ºck W, Lucchinetti C, Lassmann H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006 Dec;129(Pt 12):3165-72. Epub 2006 Aug 18. Erratum in: Brain. 2007 Mar;130(Pt 3):879.</citation>
    <PMID>16921173</PMID>
  </reference>
  <reference>
    <citation>Franklin RJ, ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012 Nov 5;8(11):624-34. doi: 10.1038/nrneurol.2012.200. Epub 2012 Oct 2. Review.</citation>
    <PMID>23026979</PMID>
  </reference>
  <reference>
    <citation>Tselis A, Khan OA, Lisak RP. Approaches to neuroprotective strategies in multiple sclerosis. Expert Opin Pharmacother. 2010 Dec;11(17):2869-78. doi: 10.1517/14656566.2010.508070. Epub 2010 Aug 5. Review.</citation>
    <PMID>20687779</PMID>
  </reference>
  <reference>
    <citation>Zhornitsky S, Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. Mult Scler. 2013 Jan;19(1):15-23. doi: 10.1177/1352458512458555. Epub 2012 Aug 29. Review.</citation>
    <PMID>22933621</PMID>
  </reference>
  <reference>
    <citation>Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997 Sep;42(3):379-82.</citation>
    <PMID>9307263</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Marcus Werner Koch</investigator_full_name>
    <investigator_title>Neurologist, Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

